Ellen Burnham
Concepts (548)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 38 | 2025 | 823 | 6.530 |
Why?
| | Bronchoalveolar Lavage Fluid | 22 | 2022 | 633 | 1.960 |
Why?
| | Respiratory Insufficiency | 10 | 2025 | 325 | 1.920 |
Why?
| | Lung | 19 | 2025 | 4042 | 1.740 |
Why?
| | Alcohol-Related Disorders | 7 | 2015 | 127 | 1.640 |
Why?
| | Cannabis | 5 | 2025 | 510 | 1.310 |
Why?
| | Intensive Care Units | 20 | 2025 | 868 | 1.290 |
Why?
| | Pneumonia | 9 | 2023 | 634 | 1.290 |
Why?
| | Ethanol | 11 | 2022 | 627 | 1.280 |
Why?
| | Acute Lung Injury | 10 | 2022 | 300 | 1.260 |
Why?
| | Respiratory Mucosa | 4 | 2020 | 324 | 1.220 |
Why?
| | Critical Illness | 21 | 2024 | 842 | 1.170 |
Why?
| | Marijuana Smoking | 3 | 2025 | 262 | 1.090 |
Why?
| | Sepsis | 6 | 2020 | 626 | 1.060 |
Why?
| | Gene Expression | 3 | 2020 | 1490 | 1.020 |
Why?
| | Macrophages, Alveolar | 9 | 2021 | 372 | 1.010 |
Why?
| | Cytokines | 9 | 2025 | 2077 | 0.960 |
Why?
| | Critical Care | 10 | 2021 | 667 | 0.940 |
Why?
| | Survivors | 8 | 2025 | 501 | 0.900 |
Why?
| | Middle Aged | 72 | 2025 | 34553 | 0.880 |
Why?
| | Inflammation Mediators | 4 | 2016 | 507 | 0.880 |
Why?
| | Central Nervous System Depressants | 2 | 2021 | 89 | 0.830 |
Why?
| | Pulmonary Alveoli | 6 | 2016 | 391 | 0.830 |
Why?
| | Acetates | 2 | 2021 | 82 | 0.820 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 59 | 0.820 |
Why?
| | Streptococcus pneumoniae | 2 | 2018 | 167 | 0.800 |
Why?
| | Stem Cells | 5 | 2015 | 604 | 0.800 |
Why?
| | Adult | 66 | 2025 | 39198 | 0.780 |
Why?
| | Pulmonary Fibrosis | 3 | 2022 | 389 | 0.770 |
Why?
| | Hospital Mortality | 7 | 2025 | 928 | 0.770 |
Why?
| | Mentors | 4 | 2014 | 213 | 0.760 |
Why?
| | Substance Withdrawal Syndrome | 4 | 2021 | 181 | 0.760 |
Why?
| | Humans | 130 | 2025 | 141010 | 0.760 |
Why?
| | Smoking | 8 | 2021 | 1572 | 0.760 |
Why?
| | Leukocytes, Mononuclear | 3 | 2017 | 571 | 0.750 |
Why?
| | Lung Diseases | 3 | 2021 | 783 | 0.740 |
Why?
| | Cerebrovascular Circulation | 2 | 2021 | 271 | 0.700 |
Why?
| | Male | 80 | 2025 | 69945 | 0.680 |
Why?
| | Female | 82 | 2025 | 75619 | 0.670 |
Why?
| | Hospitalization | 9 | 2023 | 2259 | 0.670 |
Why?
| | Behavior | 1 | 2021 | 92 | 0.670 |
Why?
| | Thalamus | 2 | 2021 | 115 | 0.660 |
Why?
| | Hypnotics and Sedatives | 4 | 2025 | 215 | 0.650 |
Why?
| | Glycerophospholipids | 4 | 2024 | 36 | 0.650 |
Why?
| | Respiration, Artificial | 13 | 2025 | 689 | 0.650 |
Why?
| | Case-Control Studies | 14 | 2022 | 3575 | 0.650 |
Why?
| | Burnout, Professional | 4 | 2022 | 453 | 0.630 |
Why?
| | Hallucinogens | 1 | 2021 | 110 | 0.610 |
Why?
| | Cigarette Smoking | 2 | 2020 | 101 | 0.590 |
Why?
| | RNA, Messenger | 5 | 2020 | 2815 | 0.580 |
Why?
| | Glutathione | 5 | 2016 | 361 | 0.570 |
Why?
| | Antioxidants | 4 | 2016 | 593 | 0.560 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2018 | 47 | 0.560 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 298 | 0.550 |
Why?
| | Epithelial Cells | 4 | 2021 | 1105 | 0.550 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 567 | 0.550 |
Why?
| | Toll-Like Receptor 2 | 2 | 2016 | 120 | 0.550 |
Why?
| | Tobacco Products | 1 | 2019 | 91 | 0.550 |
Why?
| | Xanthine Dehydrogenase | 1 | 2017 | 25 | 0.540 |
Why?
| | Physicians, Women | 1 | 2019 | 87 | 0.540 |
Why?
| | Inflammation | 8 | 2025 | 2835 | 0.540 |
Why?
| | Bronchoalveolar Lavage | 7 | 2023 | 92 | 0.530 |
Why?
| | Biomedical Research | 2 | 2021 | 681 | 0.510 |
Why?
| | Toll-Like Receptor 4 | 2 | 2016 | 275 | 0.500 |
Why?
| | Blood-Air Barrier | 2 | 2008 | 12 | 0.490 |
Why?
| | Organ Dysfunction Scores | 1 | 2016 | 52 | 0.490 |
Why?
| | Alcohol Drinking | 6 | 2025 | 834 | 0.470 |
Why?
| | Marijuana Abuse | 1 | 2018 | 230 | 0.470 |
Why?
| | Burns | 4 | 2024 | 350 | 0.460 |
Why?
| | Azithromycin | 1 | 2015 | 98 | 0.450 |
Why?
| | Tomography | 2 | 2025 | 45 | 0.440 |
Why?
| | Electric Impedance | 2 | 2025 | 112 | 0.430 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 1038 | 0.420 |
Why?
| | Research Support as Topic | 2 | 2011 | 81 | 0.420 |
Why?
| | Professional Autonomy | 1 | 2013 | 31 | 0.410 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 179 | 0.410 |
Why?
| | Aged | 33 | 2025 | 24771 | 0.400 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2762 | 0.400 |
Why?
| | Cells, Cultured | 8 | 2018 | 4149 | 0.400 |
Why?
| | Lipopolysaccharides | 5 | 2017 | 854 | 0.400 |
Why?
| | Bronchoscopy | 3 | 2023 | 225 | 0.390 |
Why?
| | Oxidative Stress | 5 | 2017 | 1322 | 0.390 |
Why?
| | Retrospective Studies | 23 | 2025 | 16389 | 0.380 |
Why?
| | Immunity, Innate | 1 | 2018 | 845 | 0.380 |
Why?
| | Drugs, Chinese Herbal | 1 | 2012 | 22 | 0.360 |
Why?
| | Asthma | 2 | 2022 | 1911 | 0.360 |
Why?
| | Academic Medical Centers | 2 | 2014 | 523 | 0.350 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2013 | 272 | 0.350 |
Why?
| | Imaging, Three-Dimensional | 2 | 2025 | 565 | 0.340 |
Why?
| | Biomarkers | 14 | 2024 | 4178 | 0.330 |
Why?
| | Venous Thromboembolism | 3 | 2020 | 337 | 0.330 |
Why?
| | Gene Expression Regulation | 6 | 2022 | 2600 | 0.330 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2009 | 11 | 0.310 |
Why?
| | Malondialdehyde | 2 | 2021 | 29 | 0.310 |
Why?
| | Personnel Selection | 1 | 2011 | 86 | 0.310 |
Why?
| | Acetaldehyde | 2 | 2021 | 17 | 0.310 |
Why?
| | Muscular Diseases | 3 | 2017 | 112 | 0.310 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2010 | 96 | 0.310 |
Why?
| | Medical Staff, Hospital | 1 | 2010 | 81 | 0.310 |
Why?
| | Pneumococcal Infections | 1 | 2010 | 108 | 0.300 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1864 | 0.300 |
Why?
| | Cohort Studies | 13 | 2020 | 5795 | 0.300 |
Why?
| | Multiple Organ Failure | 3 | 2006 | 127 | 0.290 |
Why?
| | Smokers | 2 | 2021 | 142 | 0.290 |
Why?
| | Hypoxia | 3 | 2025 | 1163 | 0.280 |
Why?
| | Epidemics | 2 | 2019 | 95 | 0.270 |
Why?
| | Burns, Inhalation | 2 | 2017 | 9 | 0.270 |
Why?
| | Pulmonary Embolism | 3 | 2019 | 238 | 0.270 |
Why?
| | Airway Extubation | 3 | 2013 | 60 | 0.270 |
Why?
| | Sexism | 2 | 2019 | 68 | 0.270 |
Why?
| | Betacoronavirus | 2 | 2020 | 277 | 0.260 |
Why?
| | Benzodiazepines | 2 | 2025 | 162 | 0.260 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2006 | 6 | 0.260 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 187 | 0.260 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1220 | 0.260 |
Why?
| | Pilot Projects | 6 | 2025 | 1817 | 0.260 |
Why?
| | Endothelial Cells | 4 | 2011 | 814 | 0.260 |
Why?
| | Multivariate Analysis | 5 | 2023 | 1504 | 0.250 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 239 | 0.250 |
Why?
| | Deglutition Disorders | 3 | 2013 | 151 | 0.250 |
Why?
| | Fibronectins | 1 | 2007 | 135 | 0.250 |
Why?
| | APACHE | 4 | 2013 | 64 | 0.250 |
Why?
| | Young Adult | 13 | 2024 | 13675 | 0.240 |
Why?
| | Marijuana Use | 2 | 2022 | 220 | 0.240 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2017 | 164 | 0.240 |
Why?
| | Administration, Inhalation | 3 | 2025 | 594 | 0.240 |
Why?
| | Preoperative Care | 1 | 2008 | 372 | 0.240 |
Why?
| | Immunity, Cellular | 2 | 2018 | 266 | 0.240 |
Why?
| | Risk Factors | 16 | 2020 | 10475 | 0.240 |
Why?
| | Polyunsaturated Alkamides | 1 | 2025 | 9 | 0.230 |
Why?
| | Anesthesiology | 1 | 2008 | 170 | 0.230 |
Why?
| | Pediatrics | 1 | 2013 | 1099 | 0.230 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1175 | 0.230 |
Why?
| | United States | 16 | 2025 | 15252 | 0.230 |
Why?
| | Tobacco Use Cessation | 1 | 2025 | 28 | 0.230 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2005 | 54 | 0.230 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 374 | 0.230 |
Why?
| | Arachidonic Acids | 1 | 2025 | 52 | 0.230 |
Why?
| | Coronavirus Infections | 2 | 2020 | 370 | 0.230 |
Why?
| | Neuromuscular Blockade | 1 | 2025 | 45 | 0.220 |
Why?
| | Flow Cytometry | 2 | 2024 | 1182 | 0.220 |
Why?
| | Propofol | 1 | 2025 | 88 | 0.220 |
Why?
| | Endocannabinoids | 1 | 2025 | 68 | 0.220 |
Why?
| | Dysbiosis | 2 | 2024 | 182 | 0.210 |
Why?
| | Immunity | 1 | 2025 | 138 | 0.210 |
Why?
| | E-Selectin | 1 | 2004 | 57 | 0.210 |
Why?
| | Patient Discharge | 3 | 2024 | 914 | 0.210 |
Why?
| | Bacterial Proteins | 1 | 2010 | 911 | 0.210 |
Why?
| | Patient Acceptance of Health Care | 3 | 2019 | 874 | 0.210 |
Why?
| | Quality of Life | 2 | 2013 | 3021 | 0.210 |
Why?
| | Patient Admission | 1 | 2025 | 203 | 0.200 |
Why?
| | Aged, 80 and over | 10 | 2022 | 7939 | 0.200 |
Why?
| | Anticoagulants | 2 | 2019 | 724 | 0.200 |
Why?
| | Immunophenotyping | 1 | 2024 | 325 | 0.200 |
Why?
| | Interleukin-1beta | 2 | 2017 | 386 | 0.200 |
Why?
| | Shock, Septic | 2 | 2022 | 213 | 0.200 |
Why?
| | Internship and Residency | 1 | 2013 | 1223 | 0.200 |
Why?
| | Lung Injury | 2 | 2016 | 221 | 0.190 |
Why?
| | Interferons | 2 | 2016 | 194 | 0.190 |
Why?
| | Dyspnea | 2 | 2019 | 258 | 0.190 |
Why?
| | Polyneuropathies | 2 | 2017 | 57 | 0.190 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 1 | 2022 | 22 | 0.190 |
Why?
| | Epithelium | 2 | 2021 | 311 | 0.180 |
Why?
| | Smoke Inhalation Injury | 2 | 2012 | 30 | 0.180 |
Why?
| | Age Factors | 4 | 2021 | 3291 | 0.180 |
Why?
| | Fibroblasts | 3 | 2013 | 1010 | 0.180 |
Why?
| | Smoking Cessation | 1 | 2025 | 431 | 0.180 |
Why?
| | Double-Blind Method | 4 | 2014 | 1979 | 0.180 |
Why?
| | Interleukin-8 | 3 | 2018 | 268 | 0.180 |
Why?
| | Alcohol Abstinence | 1 | 2021 | 13 | 0.170 |
Why?
| | Delirium | 1 | 2023 | 105 | 0.170 |
Why?
| | Societies, Medical | 2 | 2025 | 854 | 0.170 |
Why?
| | Cell Count | 2 | 2015 | 319 | 0.170 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 11 | 0.170 |
Why?
| | Status Asthmaticus | 1 | 2020 | 13 | 0.170 |
Why?
| | Neutrophils | 3 | 2017 | 1113 | 0.170 |
Why?
| | Feces | 1 | 2024 | 488 | 0.170 |
Why?
| | Phagocytosis | 2 | 2014 | 291 | 0.160 |
Why?
| | Physicians | 3 | 2022 | 929 | 0.160 |
Why?
| | Pandemics | 4 | 2022 | 1655 | 0.160 |
Why?
| | Random Allocation | 1 | 2021 | 369 | 0.160 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2018 | 343 | 0.160 |
Why?
| | Animals | 18 | 2025 | 37304 | 0.160 |
Why?
| | Comorbidity | 4 | 2020 | 1671 | 0.160 |
Why?
| | Capacity Building | 1 | 2020 | 59 | 0.160 |
Why?
| | Immunoglobulin A | 1 | 2021 | 214 | 0.160 |
Why?
| | Permeability | 2 | 2012 | 163 | 0.160 |
Why?
| | Career Choice | 2 | 2012 | 233 | 0.160 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1117 | 0.150 |
Why?
| | Chemokines | 2 | 2018 | 223 | 0.150 |
Why?
| | Cardiology | 1 | 2022 | 281 | 0.150 |
Why?
| | von Willebrand Factor | 1 | 2019 | 84 | 0.150 |
Why?
| | Homeostasis | 1 | 2003 | 630 | 0.150 |
Why?
| | Disaster Planning | 1 | 2020 | 96 | 0.150 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.150 |
Why?
| | Prevalence | 3 | 2025 | 2792 | 0.150 |
Why?
| | Faculty, Medical | 1 | 2022 | 289 | 0.150 |
Why?
| | Needs Assessment | 1 | 2021 | 385 | 0.150 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 38 | 0.150 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 941 | 0.150 |
Why?
| | Macrolides | 1 | 2019 | 69 | 0.150 |
Why?
| | Wounds and Injuries | 1 | 2006 | 916 | 0.140 |
Why?
| | Brain | 3 | 2021 | 2857 | 0.140 |
Why?
| | Pyridines | 2 | 2010 | 555 | 0.140 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 7 | 0.140 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 344 | 0.140 |
Why?
| | Statistics, Nonparametric | 4 | 2014 | 432 | 0.140 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.140 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 23 | 0.140 |
Why?
| | Length of Stay | 4 | 2020 | 1264 | 0.140 |
Why?
| | Apoptosis | 3 | 2014 | 2479 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 26 | 0.140 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2018 | 25 | 0.140 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 83 | 0.140 |
Why?
| | Cardiologists | 1 | 2018 | 46 | 0.140 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 176 | 0.140 |
Why?
| | Decision Making | 1 | 2025 | 949 | 0.140 |
Why?
| | Occupational Therapy | 1 | 2019 | 97 | 0.130 |
Why?
| | Hospitals, University | 2 | 2015 | 176 | 0.130 |
Why?
| | Chemokine CCL2 | 1 | 2017 | 115 | 0.130 |
Why?
| | Heparin | 1 | 2019 | 254 | 0.130 |
Why?
| | Pyrazoles | 1 | 2001 | 482 | 0.130 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 181 | 0.130 |
Why?
| | Interleukin-1 | 1 | 2001 | 970 | 0.130 |
Why?
| | Tobacco Use | 1 | 2017 | 65 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 983 | 0.130 |
Why?
| | Cyclooxygenase 2 | 1 | 2017 | 172 | 0.130 |
Why?
| | Cystine | 1 | 2016 | 18 | 0.130 |
Why?
| | Transforming Growth Factor beta | 3 | 2022 | 478 | 0.130 |
Why?
| | Interleukin-10 | 1 | 2018 | 305 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2016 | 547 | 0.130 |
Why?
| | Interleukin-6 | 2 | 2018 | 775 | 0.120 |
Why?
| | Treatment Outcome | 9 | 2022 | 11195 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1336 | 0.120 |
Why?
| | Disulfides | 1 | 2016 | 99 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2021 | 4400 | 0.120 |
Why?
| | Hospitalists | 1 | 2020 | 243 | 0.120 |
Why?
| | Substance-Related Disorders | 1 | 2025 | 1100 | 0.120 |
Why?
| | Teichoic Acids | 1 | 2016 | 14 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 716 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2014 | 5212 | 0.120 |
Why?
| | DNA, Bacterial | 1 | 2017 | 333 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2001 | 855 | 0.120 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 286 | 0.120 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 320 | 0.120 |
Why?
| | RNA Splicing | 1 | 2017 | 271 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 180 | 0.120 |
Why?
| | Proteins | 2 | 2021 | 1007 | 0.120 |
Why?
| | Inflammasomes | 1 | 2017 | 143 | 0.120 |
Why?
| | Hospitals | 1 | 2020 | 688 | 0.120 |
Why?
| | Patient Selection | 2 | 2023 | 685 | 0.120 |
Why?
| | Alternative Splicing | 1 | 2017 | 232 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 101 | 0.110 |
Why?
| | Cysteine | 1 | 2016 | 208 | 0.110 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2022 | 657 | 0.110 |
Why?
| | Acetylcysteine | 1 | 2016 | 144 | 0.110 |
Why?
| | Urinary Bladder | 1 | 2017 | 194 | 0.110 |
Why?
| | Cannabinoids | 1 | 2017 | 178 | 0.110 |
Why?
| | Cholesterol | 1 | 2017 | 404 | 0.110 |
Why?
| | Interprofessional Relations | 1 | 2017 | 281 | 0.110 |
Why?
| | Signal Transduction | 3 | 2022 | 5114 | 0.110 |
Why?
| | Oxidation-Reduction | 2 | 2016 | 1080 | 0.110 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2012 | 153 | 0.110 |
Why?
| | Severity of Illness Index | 5 | 2016 | 2903 | 0.100 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 68 | 0.100 |
Why?
| | Transcriptome | 1 | 2020 | 1007 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1243 | 0.100 |
Why?
| | Third-Party Consent | 1 | 2013 | 20 | 0.100 |
Why?
| | Competency-Based Education | 1 | 2014 | 75 | 0.100 |
Why?
| | Professional Competence | 1 | 2014 | 96 | 0.100 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 43 | 0.100 |
Why?
| | Total Lung Capacity | 1 | 2013 | 32 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 413 | 0.100 |
Why?
| | Reproducibility of Results | 3 | 2019 | 3342 | 0.100 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2013 | 40 | 0.100 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2013 | 76 | 0.100 |
Why?
| | Disease Progression | 1 | 2020 | 2794 | 0.100 |
Why?
| | Financial Support | 1 | 2012 | 17 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2017 | 402 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1234 | 0.100 |
Why?
| | Speech-Language Pathology | 1 | 2012 | 23 | 0.100 |
Why?
| | Aging | 2 | 2017 | 1919 | 0.100 |
Why?
| | Interleukin-12 | 1 | 2013 | 122 | 0.100 |
Why?
| | Logistic Models | 5 | 2017 | 2097 | 0.100 |
Why?
| | Transcription, Genetic | 2 | 2010 | 1486 | 0.090 |
Why?
| | Cell Survival | 1 | 2015 | 1123 | 0.090 |
Why?
| | Informed Consent | 1 | 2013 | 186 | 0.090 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 62 | 0.090 |
Why?
| | Neuregulin-1 | 1 | 2012 | 48 | 0.090 |
Why?
| | Vital Capacity | 1 | 2013 | 305 | 0.090 |
Why?
| | Acute Disease | 2 | 2025 | 1005 | 0.090 |
Why?
| | Pepsin A | 1 | 2011 | 18 | 0.090 |
Why?
| | Serotonin | 1 | 2014 | 289 | 0.090 |
Why?
| | Ubiquitin | 1 | 2012 | 72 | 0.090 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 83 | 0.090 |
Why?
| | Lipid Peroxidation | 1 | 2012 | 150 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3731 | 0.090 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 32 | 0.090 |
Why?
| | Phytotherapy | 1 | 2012 | 82 | 0.090 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 558 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 849 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 693 | 0.080 |
Why?
| | Prospective Studies | 6 | 2021 | 7797 | 0.080 |
Why?
| | Capillaries | 2 | 2009 | 121 | 0.080 |
Why?
| | Genetic Testing | 1 | 2013 | 462 | 0.080 |
Why?
| | Research Design | 2 | 2011 | 1105 | 0.080 |
Why?
| | Night Care | 1 | 2010 | 4 | 0.080 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2011 | 82 | 0.080 |
Why?
| | After-Hours Care | 1 | 2010 | 17 | 0.080 |
Why?
| | Feasibility Studies | 2 | 2025 | 1025 | 0.080 |
Why?
| | Nervous System Diseases | 1 | 2013 | 278 | 0.080 |
Why?
| | Collagen | 1 | 2012 | 452 | 0.080 |
Why?
| | Awards and Prizes | 1 | 2011 | 72 | 0.080 |
Why?
| | Autoantibodies | 1 | 2017 | 1466 | 0.080 |
Why?
| | ROC Curve | 2 | 2017 | 591 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2015 | 1983 | 0.080 |
Why?
| | Colony-Forming Units Assay | 1 | 2009 | 94 | 0.080 |
Why?
| | Colorado | 5 | 2024 | 4595 | 0.080 |
Why?
| | Organizational Culture | 1 | 2011 | 162 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 753 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1545 | 0.080 |
Why?
| | Peer Group | 1 | 2011 | 247 | 0.070 |
Why?
| | Program Development | 1 | 2011 | 364 | 0.070 |
Why?
| | Mice | 7 | 2022 | 17945 | 0.070 |
Why?
| | Gastroesophageal Reflux | 1 | 2011 | 244 | 0.070 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 8 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2022 | 414 | 0.070 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2008 | 7 | 0.070 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5849 | 0.070 |
Why?
| | Computers | 1 | 2008 | 68 | 0.070 |
Why?
| | Hypertension, Pulmonary | 2 | 2011 | 1939 | 0.070 |
Why?
| | Radionuclide Imaging | 1 | 2008 | 117 | 0.070 |
Why?
| | Half-Life | 1 | 2008 | 145 | 0.070 |
Why?
| | Focus Groups | 1 | 2011 | 565 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2011 | 322 | 0.070 |
Why?
| | Chest Pain | 1 | 2008 | 96 | 0.070 |
Why?
| | Quality Assurance, Health Care | 1 | 2010 | 319 | 0.070 |
Why?
| | Burn Units | 2 | 2022 | 48 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 2047 | 0.070 |
Why?
| | Schools | 1 | 2011 | 451 | 0.070 |
Why?
| | Radiopharmaceuticals | 1 | 2008 | 189 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 147 | 0.070 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 28 | 0.070 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 434 | 0.070 |
Why?
| | Multicenter Studies as Topic | 2 | 2022 | 365 | 0.070 |
Why?
| | Sex Factors | 1 | 2013 | 2048 | 0.060 |
Why?
| | Patient Readmission | 3 | 2019 | 695 | 0.060 |
Why?
| | Cell Separation | 3 | 2016 | 309 | 0.060 |
Why?
| | Indicators and Reagents | 1 | 2007 | 108 | 0.060 |
Why?
| | Georgia | 2 | 2004 | 87 | 0.060 |
Why?
| | Respiration Disorders | 1 | 2007 | 79 | 0.060 |
Why?
| | Cocaine-Related Disorders | 1 | 2008 | 136 | 0.060 |
Why?
| | NIH 3T3 Cells | 1 | 2007 | 148 | 0.060 |
Why?
| | Body Fluids | 1 | 2007 | 70 | 0.060 |
Why?
| | Pulmonary Artery | 2 | 2013 | 1115 | 0.060 |
Why?
| | Program Evaluation | 1 | 2011 | 919 | 0.060 |
Why?
| | Thrombocytopenia | 2 | 2019 | 206 | 0.060 |
Why?
| | Stem Cell Transplantation | 1 | 2008 | 186 | 0.060 |
Why?
| | Nursing Staff, Hospital | 1 | 2009 | 160 | 0.060 |
Why?
| | Matrix Metalloproteinases | 1 | 2007 | 95 | 0.060 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 649 | 0.060 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 5648 | 0.060 |
Why?
| | Propensity Score | 2 | 2017 | 335 | 0.060 |
Why?
| | Pneumonia, Bacterial | 1 | 2006 | 116 | 0.060 |
Why?
| | Louisiana | 1 | 2024 | 26 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2013 | 1996 | 0.050 |
Why?
| | Adolescent | 6 | 2022 | 22066 | 0.050 |
Why?
| | Observation | 1 | 2004 | 56 | 0.050 |
Why?
| | Respiration | 1 | 2025 | 209 | 0.050 |
Why?
| | Fatty Acids, Volatile | 1 | 2024 | 60 | 0.050 |
Why?
| | Dimercaprol | 1 | 2023 | 6 | 0.050 |
Why?
| | Hemorrhage | 2 | 2019 | 787 | 0.050 |
Why?
| | Hand Strength | 1 | 2024 | 132 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2726 | 0.050 |
Why?
| | Hydroxyethyl Starch Derivatives | 1 | 2003 | 9 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 104 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1445 | 0.050 |
Why?
| | Time Factors | 4 | 2018 | 6939 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5932 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 36 | 0.050 |
Why?
| | Nutritional Status | 1 | 2005 | 357 | 0.050 |
Why?
| | Adaptive Clinical Trials as Topic | 1 | 2022 | 25 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 74 | 0.050 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2022 | 55 | 0.050 |
Why?
| | rhoA GTP-Binding Protein | 2 | 2014 | 75 | 0.050 |
Why?
| | Vasopressins | 1 | 2022 | 60 | 0.040 |
Why?
| | North America | 1 | 2022 | 304 | 0.040 |
Why?
| | Receptors, Polymeric Immunoglobulin | 1 | 2021 | 2 | 0.040 |
Why?
| | rho-Associated Kinases | 2 | 2014 | 81 | 0.040 |
Why?
| | Transcytosis | 1 | 2021 | 7 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 342 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 136 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 189 | 0.040 |
Why?
| | Blood Alcohol Content | 1 | 2021 | 5 | 0.040 |
Why?
| | Naltrexone | 1 | 2022 | 101 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 200 | 0.040 |
Why?
| | Bleomycin | 1 | 2022 | 238 | 0.040 |
Why?
| | Cilia | 1 | 2022 | 170 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2021 | 3041 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 665 | 0.040 |
Why?
| | Containment of Biohazards | 1 | 2020 | 21 | 0.040 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2009 | 862 | 0.040 |
Why?
| | Recombinant Proteins | 2 | 2015 | 1362 | 0.040 |
Why?
| | Rats | 2 | 2017 | 5556 | 0.040 |
Why?
| | Intersectoral Collaboration | 1 | 2020 | 59 | 0.040 |
Why?
| | Protein Transport | 1 | 2021 | 446 | 0.040 |
Why?
| | Medical Oncology | 1 | 2022 | 316 | 0.040 |
Why?
| | Prognosis | 3 | 2013 | 4073 | 0.040 |
Why?
| | Incidence | 2 | 2003 | 2802 | 0.040 |
Why?
| | Pharmacoepidemiology | 1 | 2019 | 21 | 0.040 |
Why?
| | Chronic Disease | 3 | 2015 | 1806 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 167 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 324 | 0.040 |
Why?
| | Coronary Circulation | 1 | 2018 | 134 | 0.030 |
Why?
| | Qualitative Research | 1 | 2025 | 1510 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2018 | 44 | 0.030 |
Why?
| | Leadership | 1 | 2022 | 387 | 0.030 |
Why?
| | Illinois | 1 | 2017 | 44 | 0.030 |
Why?
| | Hospital Charges | 1 | 2017 | 44 | 0.030 |
Why?
| | RNA Transport | 1 | 2017 | 25 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 137 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 163 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2022 | 680 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 99 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 824 | 0.030 |
Why?
| | Algorithms | 1 | 2024 | 1761 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 713 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2019 | 192 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2025 | 1393 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2921 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 331 | 0.030 |
Why?
| | Dried Blood Spot Testing | 1 | 2017 | 121 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 381 | 0.030 |
Why?
| | RNA Precursors | 1 | 2017 | 156 | 0.030 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2016 | 29 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 12 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2008 | 2824 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 306 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2017 | 249 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2016 | 133 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 452 | 0.030 |
Why?
| | Risk | 1 | 2018 | 903 | 0.030 |
Why?
| | Cause of Death | 1 | 2017 | 445 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 195 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 513 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 855 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 948 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 542 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 244 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 212 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1226 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 815 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2069 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 196 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 910 | 0.030 |
Why?
| | Mental Competency | 1 | 2013 | 25 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1057 | 0.030 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 8 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2014 | 328 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1322 | 0.020 |
Why?
| | Ventilator Weaning | 1 | 2013 | 39 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor D | 1 | 2012 | 12 | 0.020 |
Why?
| | Phylogeny | 1 | 2017 | 996 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2012 | 16 | 0.020 |
Why?
| | Lymphangiogenesis | 1 | 2012 | 26 | 0.020 |
Why?
| | Thymus Gland | 1 | 2014 | 316 | 0.020 |
Why?
| | Tidal Volume | 1 | 2013 | 103 | 0.020 |
Why?
| | Biological Transport | 1 | 2014 | 409 | 0.020 |
Why?
| | Fibrosis | 1 | 2015 | 541 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2013 | 143 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2012 | 132 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2015 | 734 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 522 | 0.020 |
Why?
| | Observer Variation | 1 | 2012 | 355 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 481 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 673 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2233 | 0.020 |
Why?
| | Bronchiolitis Obliterans | 1 | 2011 | 64 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2017 | 2511 | 0.020 |
Why?
| | World Health Organization | 1 | 2011 | 103 | 0.020 |
Why?
| | Microbial Viability | 1 | 2011 | 91 | 0.020 |
Why?
| | Research Personnel | 1 | 2012 | 177 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2012 | 418 | 0.020 |
Why?
| | Superoxides | 1 | 2011 | 208 | 0.020 |
Why?
| | Proteomics | 1 | 2017 | 1137 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2015 | 554 | 0.020 |
Why?
| | Immunomodulation | 1 | 2011 | 100 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 272 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 845 | 0.020 |
Why?
| | Blood Pressure | 1 | 2017 | 1740 | 0.020 |
Why?
| | Species Specificity | 1 | 2011 | 573 | 0.020 |
Why?
| | rho GTP-Binding Proteins | 1 | 2010 | 55 | 0.020 |
Why?
| | Amides | 1 | 2010 | 97 | 0.020 |
Why?
| | Injury Severity Score | 1 | 2012 | 570 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 463 | 0.020 |
Why?
| | Metabolomics | 1 | 2015 | 702 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 386 | 0.020 |
Why?
| | Lung Compliance | 1 | 2009 | 46 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1753 | 0.020 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2011 | 230 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1761 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1069 | 0.020 |
Why?
| | Physician-Nurse Relations | 1 | 2009 | 18 | 0.020 |
Why?
| | Viruses | 1 | 2011 | 163 | 0.020 |
Why?
| | Leisure Activities | 1 | 2009 | 30 | 0.020 |
Why?
| | AC133 Antigen | 1 | 2008 | 20 | 0.020 |
Why?
| | Cell Fusion | 1 | 2008 | 49 | 0.020 |
Why?
| | Giant Cells | 1 | 2008 | 22 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2008 | 50 | 0.020 |
Why?
| | Mitochondria | 1 | 2015 | 962 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2008 | 88 | 0.020 |
Why?
| | Thyroxine | 1 | 2008 | 63 | 0.020 |
Why?
| | Nurse Administrators | 1 | 2009 | 45 | 0.020 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2009 | 83 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 771 | 0.020 |
Why?
| | Osteocytes | 1 | 2008 | 30 | 0.020 |
Why?
| | Breath Tests | 1 | 2007 | 77 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 267 | 0.020 |
Why?
| | Databases as Topic | 1 | 2007 | 68 | 0.020 |
Why?
| | Curriculum | 1 | 2014 | 1031 | 0.020 |
Why?
| | Child | 2 | 2022 | 22337 | 0.020 |
Why?
| | Social Environment | 1 | 2009 | 294 | 0.020 |
Why?
| | Laparoscopy | 1 | 2011 | 463 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 511 | 0.020 |
Why?
| | Cell Movement | 1 | 2011 | 962 | 0.020 |
Why?
| | Glycoproteins | 1 | 2008 | 354 | 0.020 |
Why?
| | Job Satisfaction | 1 | 2009 | 223 | 0.020 |
Why?
| | Models, Biological | 1 | 2014 | 1810 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 550 | 0.020 |
Why?
| | Adipocytes | 1 | 2008 | 220 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 334 | 0.010 |
Why?
| | Trauma Centers | 1 | 2009 | 453 | 0.010 |
Why?
| | Cell Lineage | 1 | 2008 | 352 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1604 | 0.010 |
Why?
| | Antigens, CD | 1 | 2008 | 536 | 0.010 |
Why?
| | Chondrocytes | 1 | 2008 | 229 | 0.010 |
Why?
| | Telomerase | 1 | 2008 | 249 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1490 | 0.010 |
Why?
| | Health Care Costs | 1 | 2007 | 417 | 0.010 |
Why?
| | France | 1 | 2003 | 38 | 0.010 |
Why?
| | Contraindications | 1 | 2003 | 86 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 971 | 0.010 |
Why?
| | Washington | 1 | 2003 | 159 | 0.010 |
Why?
| | Cardiac Output | 1 | 2003 | 177 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2502 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2003 | 1312 | 0.010 |
Why?
|
|
Burnham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|